Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Study limitation reported by the research below: “No active comparator was used, so relative efficacy versus approved agents (semaglutide, tirzepatide) in this population cannot be determined from this trial.”